Novo Nordisk to pay $300M upfront for global rights to Hengrui's HRS-1596, deal worth up to $2.6B

Novo Nordisk will pay $300 million upfront for global rights to Hengrui's HRS-1596, in a licensing deal worth up to $2.6 billion in total milestones and payments.

Detected & updated continuously · Source: Nebula